1.75 CME

Sindrom metabolik pada wanita dengan PCOS

Pembicara: Dr. Krishna Kumari

Alumni- Sekolah Tinggi Kedokteran Andhra

Masuk untuk Memulai

Keterangan

Metabolic syndrome is a common and significant concern in women with Polycystic Ovary Syndrome (PCOS), characterized by a cluster of conditions including insulin resistance, obesity, dyslipidemia, and hypertension. These interconnected metabolic disturbances increase the risk of developing cardiovascular diseases and type 2 diabetes. Insulin resistance, a hallmark of PCOS, exacerbates hyperandrogenism, leading to further metabolic and reproductive complications. Women with PCOS often struggle with weight management, contributing to the prevalence of obesity within this population, which in turn aggravates insulin resistance and other metabolic abnormalities. Dyslipidemia, marked by elevated triglycerides and low HDL cholesterol, is frequently observed in these women, further elevating cardiovascular risk. The management of metabolic syndrome in PCOS involves a multifaceted approach, including lifestyle modifications such as diet and exercise, pharmacological interventions like insulin sensitizers (e.g., metformin), and addressing individual components of the syndrome to mitigate long-term health risks. Early detection and comprehensive management of metabolic syndrome are crucial in improving the overall health outcomes for women with PCOS.

Ringkasan

  • PCOS is a heterogeneous endocrine and lifestyle disorder with long-term metabolic implications, including infertility, menstrual disturbances, hyperandrogenism, and metabolic syndrome. Early intervention and lifestyle modifications are crucial for managing the condition and preventing long-term complications.
  • The Rotterdam criteria, including hyperandrogenemia, menstrual irregularity, and polycystic ovarian morphology, are widely used for diagnosing PCOS. Phenotypes of PCOS range from classical (all three features present) to variations with different combinations of the criteria, impacting the long-term risks.
  • PCOS pathogenesis involves congenital and postnatal factors, with functional ovarian hyperandrogenism being a key feature. Insulin resistance, hyperinsulinemia, and obesity exacerbate the condition, creating a cyclical relationship between these factors.
  • Insulin resistance is prevalent in PCOS, affecting various systems like lipid metabolism, liver function, and glucose transport. This contributes to dyslipidemia, decreased sex hormone-binding globulin, and dysglycemia, potentially leading to type 2 diabetes mellitus.
  • Women with PCOS have an increased risk of developing type 2 diabetes, even if they are lean. Gestational diabetes (GDM) is also more common in pregnant women with PCOS, necessitating careful assessment and management of glycemic status.
  • Dislipidemia, hypertension, cardiovascular disease, and non-alcoholic fatty liver disease are all significant long-term risks associated with PCOS. Management includes lifestyle modifications, insulin sensitizers, statins, and antihypertensive medications.
  • Lifestyle interventions, including diet and exercise, are the first-line treatment for PCOS. Insulin sensitizers like metformin can be used to manage insulin resistance. In addition, considering newer treatments like glp1 receptor antagonist may be beneficial.
  • Regular screening for metabolic risk factors, including blood pressure, BMI, waist-hip ratio, lipid profile, and oral glucose tolerance test, is essential. Managing these risk factors can significantly reduce the long-term health complications associated with PCOS.

Komentar